Study: Amgen drug may bring new approach to treat ITP

12/10/2007 | Bloomberg

Amgen's experimental treatment for idiopathic thrombocytopenic purpura not only reduced the risk of severe bleeding, but also helped preserve a healthy number of platelets in patients with the immune disorder, scientists revealed. The biotech firm is seeking FDA approval to market the drug, labeled AMG-531, while it ramps up development to launch the product as the first to stimulate platelets to treat ITP.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ